FDA accepts priority review for leniolisib for treatment of APDS
The U.S. Food and Drug Administration has accepted for priority review a New Drug Application (NDA) for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older in the US, according to a press release. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29, 2023, aligned with a Priority Review classification.
The submission was supposed by phase II/III study data of leniolisib, which met its co-primary endpoints of reduction in index lymph node size and correction of immunodeficiency in the target population.
Read the full press release here.
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809